Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray

Laboratory Investigation

Volumn 84, Issue 2, 2004, Pages 235-244

  Zha, Hongbin ^a   Raffeld, Mark ^a   Charboneau, Lu ^a   Pittaluga, Stefania ^a   Kwak, Larry W ^a   Petricoin III, Emanuel ^b   Liotta, Lance A ^a   Jaffe, Elaine S ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Bcl 2; Follicular lymphoma; Protein microarray; Proteomics

Indexed keywords

GENE PRODUCT; PROTEIN ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SURVIVIN; AKT1 PROTEIN, HUMAN; BAD PROTEIN, HUMAN; BAXPSI PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; CARRIER PROTEIN; DNA; IMMUNOGLOBULIN HEAVY CHAIN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN BAD; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NICK END LABELING; OVARY FOLLICLE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; CANCER STAGING; CELL DIVISION; CELL SURVIVAL; GENE REARRANGEMENT; GENETICS; IMAGE PROCESSING; LYMPH NODE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEOMICS;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARRIER PROTEINS; CELL DIVISION; CELL SURVIVAL; DNA, NEOPLASM; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LYMPH NODES; LYMPHOMA, FOLLICULAR; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 1542608799     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700051     Document Type: Article

References (66)

1. Yunis JJ, Oken MM, Kaplan ME, et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982;307:1231-1236.
2. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-1099.
3. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
4. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-1393.
5. Graninger WB, Seto M, Boutain B, et al. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987;80:1512-1515.
6. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
7. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
8. Skinnider BF, Horsman DE, Dupuis B, et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999;30:803-808.
9. Logsdon MD, Meyn Jr RE, Besa PC, et al. Apoptosis and the Bcl-2 gene family - patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 1999;44:19-29.
10. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528-2536.
11. Paltiel O, Zelenetz A, Sverdlin I, et al. Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure. Ann Oncol 2000;11(Suppl 1):75-80.
12. Aster JC, Kobayashi Y, Shiota M, et al. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 1992;141:291-299.
13. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991;349:254-256.
14. Agarwal B, Naresh KN. Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases. Am J Hematol 2002;70:278-282.
15. Krajewski S, Bodrug S, Gascoyne R, et al. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994;145:515-525.
16. Rochaix P, Krajewski S, Reed JC, et al. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999;187:410-415.
17. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002;62:3244-3250.
18. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003;100:7259-7264.
19. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003;100:2639-2644.
20. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003;3:317-325.
21. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-1989.
22. Jaffe ES, Raffeld M. Malignancies of the lymphoid and histiocytic systems. In: Rose NR, Hamilton RG, Detrick B (eds). Manual of Clinical Laboratory Immunology, 6th edn. ASM Press: Washington, DC, 2002, pp 1098-1107.
23. Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:3376-3382.
24. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
25. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003;3:2091-2100.
26. Stetler-Stevenson M, Raffeld M, Cohen P, et al. Detection of occult follicular lymphoma by specific DNA amplification. Blood 1988;72:1822-1825.
27. Cossman J, Fend F, Staudt L, et al. Application of molecular genetics to the diagnosis and classification of malignant lymphoma. In: Knowles DM (ed). Neoplastic Hematopathology, 2nd edn. Lippincott, Williams and Wilkins: Philadelphia, PA, 2001, pp. 365-390.
28. Weiss LM, Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987;317:1185-1189.
29. Lipponen P, Aaltomaa S, Kosma VM, et al. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994;30A:2068-2073.
30. Wang S, Rowe M, Lundgren E. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-4613.
31. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
32. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-5037.
33. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-3641.
34. Ruggeri BA, Huang L, Wood M, et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998;21:81-86.
35. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-6111.
36. Jaffe ES, Shevach EM, Frank MM, et al. Nodular lymphoma-evidence for origin from follicular B lymphocytes. N Engl J Med 1974;290:813-819.
37. Warnke R, Levy R. Immunopathology of follicular lymphomas. A model of B-lymphocyte homing. N Engl J Med 1978;298:481-486.
38. Stamatopoulos K, Kosmas C, Belessi C, et al. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000;21:298-305.
39. Gaulard P, d'Agay M, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140:1089-1095.
40. Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998;91:244-251.
41. Horsman DE, Okamoto I, Ludkovski O, et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol 2003;120:424-433.
42. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-199.
43. Lomo J, Blomhoff HK, Jacobsen SE, et al. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood 1997;89:4415-4424.
44. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-192.
45. Wheaton S, Netser J, Guinee D, et al. Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas. Hum Pathol 1998;29:820-825.
46. Meijerink JP, Smetsers TF, Sloetjes AW, et al. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995;9:1828-1832.
47. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-969.
48. Ionov Y, Yamamoto H, Krajewski S, et al. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000;97:10872-10877.
49. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
50. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
51. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
52. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-689.
53. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-628.
54. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98:2853-2855.
55. Abbott RT, Tripp S, Perkins SL, et al. Analysis of the PI-3-kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod Pathol 2003;16:607-612.
56. Lin MT, Lee RC, Yang PC, et al. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-49002.
57. Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001;20:5799-5809.
58. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321.
59. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
60. Ozes ON, Mayo LD, Gustin JA, et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85.
61. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
62. Rena G, Guo S, Cichy SC, et al. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 1999;274:17179-17183.
63. Kurland JF, Voehringer DW, Meyn RE. The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem 2003;278:32465-32470.
64. Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am J Pathol 2002;160:759-763.
65. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003;101:1149-1154.
66. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99:3806-3812.